Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season

NCT01007721 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis, Allergic, Seasonal
Asthma

Interventions

DRUG: BI 67100 ED 25 mg
DRUG: BI 671800 ED placebo
DRUG: montelukast placebo tablet
DRUG: montelukast placebo tablet
DRUG: fluticasone propionate placebo nasal spray
DRUG: fluticasone propionate placebo nasal spray
DRUG: fluticasone propionate placebo nasal spray
DRUG: BI 671800 ED 100 mg
DRUG: BI 671800 ED placebo
DRUG: BI 671800 ED placebo
DRUG: BI 671800 ED placebo
DRUG: BI 671800 ED 100 mg
DRUG: 671800 ED placebo
DRUG: montelukast placebo tablet
DRUG: montelukast placebo tablet
DRUG: montelukast placebo tablet
DRUG: montelukast 10 mg tablet
DRUG: fluticasone propionate placebo nasal spray
DRUG: fluticasone propionate nasal spray placebo
DRUG: Fluticasonepropionate nasal spray 200 mcg

Sponsor

Boehringer Ingelheim